Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, today announced a secondary analysis from the SEISMIC-HF I study on the performance of an AI algorithm for noninvasive congestion assessment at the point of care. The new analysis will be presented by Marat Fudim, MD, Associate Professor of Medicine at Duke University Health System, as a moderated poster session at the American Heart Association's (AHA) 2025 Scientific Sessions.

“Our goal at Cardiosense is to deliver patients and providers with more proactive, precise, and widely accessible heart failure management,” said Andrew Carek, PhD, Co-founder and Chief Technology Officer at Cardiosense. “Early analysis indicates that our AI algorithm has the potential to exceed the performance of the standard physical exam in noninvasively assessing congestion. That’s a profound step toward helping clinicians make faster, data-driven decisions in outpatient and low-acuity settings.”

The new analysis shows that the Cardiosense platform is capable of providing a point-of-care tool to rapidly identify hemodynamic congestion, helping doctors make faster, more informed care decisions with the aim of improving patient outcomes.

Details of the moderated poster session are as follows:

Title: Point-of-care Non-invasive Classification of Elevated Intracardiac Filling Pressures for Congestion Assessment

Session: Iron Deficiency and Volume Overload: Tackling Symptom Burden in Heart Failure

Date: November 8

Time: 12:15–1:25 pm Central Time

Location: Clinical Science Zone 2‚ Moderated Digital Poster 19 HF.MDP.25

Presentation ID: MP812

AHA’s 2025 Scientific Sessions will be held November 7–10 at the Ernest N. Morial Convention Center in New Orleans, LA. For more information, please visit the AHA 2025 Scientific Sessions website at professional.heart.org/en/meetings/scientific-sessions.

About Cardiosense

Cardiosense is a digital health company pioneering AI-enabled solutions for precision cardiac care. Its platform leverages advanced biosensors and predictive analytics to enable early detection of cardiac disease and intervention, with the goal of leveraging personalized therapy to reduce hospitalizations, improve outcomes, and lower healthcare costs. Headquartered in Chicago, Cardiosense has advanced its platform with regulatory clearance and peer-reviewed clinical validation to shape the future of heart health. For more information, visit www.cardiosense.com and follow Cardiosense on LinkedIn and X.

The CardioTag™ device has been cleared to market as a class II medical device.

PCWP Analysis Software is pending FDA approval.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106217591/en/